Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 15/20 | 0.57 |
| ▸ | CTSK | P43235 | 14/20 | 0.57 |
| ▸ | CTSL | P07711 | 2/20 | 0.48 |
| ▸ | CTSB | P07858 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1722314 | 1.00 | CTSS (0.57) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL12602587 | 0.87 | CTSK (0.59) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL4795008 | 0.87 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL4795003 | 0.87 | CTSS (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL8357414 | 0.84 | CTSK (0.61) | CTSSCTSK | |
| SCHEMBL7855743 | 0.84 | CTSS (0.55) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL9697740 | 0.84 | CTSS (0.52) | CTSSCTSKCTSLCTSBSYK | |
| SCHEMBL31086524 | 0.84 | CYP2D6 (0.50) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL16839646 | 0.84 | SYK (0.48) | CTSSCTSKCTSLCTSBCA1 | |
| SCHEMBL29254679 | 0.84 | CTSS (0.51) | CTSSCTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | ELI LILLY AND COMPANY (US) | 2008-10-30 | — | — | US | disclosed |
| EP-1761521-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| EP-1425270-B1 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | PFIZER PROD INC (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2006012093-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-02-02 | — | — | WO | disclosed |
| EP-1383734-B1 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PROD INC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1425270-A2 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | Pfizer Products Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6706881-B2 | 4-(METHOXYCARBONYL-AMINO)-2-ETHYL-6-TRIFLUOROMETHYL-3,4-DIHYDRO -2H-QUINOLINE-1-CARBOXYLIC ACID ETHYL ESTER IS REACTED WITH 3,5-BIS(TRIFLUOROMETHYL)BENZYL HALIDE IN BASE; ALKYLATION | PFIZER, INC. | 2004-03-16 | — | — | US | disclosed |
| US-6689897-B2 | CHOLESTERYL ESTER TRANSFER PROTEIN | PFIZER INC. | 2004-02-10 | — | — | US | disclosed |
| WO-2002088069-A9 | COMPOUNDS USEFUL AS INTERMEDIATES FOR 4-AMINOQUINOLINE DERIVATIVES | PFIZER PROD INC (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030216576-A1 | Methods for preparing CETP inhibitors | PFIZER INC. | 2003-11-20 | — | — | US | disclosed |
| US-6600045-B2 | This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors and intermediates useful in the preparation of said CETP inhibitors. | PFIZER INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030073843-A1 | Methods for preparing CETP inhibitors | DAMON DAVID B (US) | 2003-04-17 | — | — | US | disclosed |
| US-20020177716-A1 | Intermediates of CETP inhibitors | DAMON DAVID B (US) | 2002-11-28 | — | — | US | disclosed |
| WO-2002088085-A2 | METHODS AND INTERMEDIATES FOR PREPARING 4-AMINOQUINOLINE CETP INHIBITORS | PFIZER PRODUCTS INC. (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216576-A1 | Methods for preparing CETP inhibitors | CETP, LCAT, MTTP | CTSS 400/4885CTSK 570/4885CTSL 272/4885 |
| US-20030073843-A1 | Methods for preparing CETP inhibitors | CETP, LCAT, MTTP | CTSS 400/4885CTSK 570/4885CTSL 272/4885 |
| US-20020177716-A1 | Intermediates of CETP inhibitors | CETP, LCAT, MTTP | CTSS 379/4885CTSK 362/4885CTSL 464/4885 |
| US-20080269284-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, PCSK9, LIPC | CTSS 2337/4885CTSK 2003/4885CTSL 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.